Skip to main content
LNTH logo

LNTH · Lantheus Holdings, Inc.

Track LNTH — free
$100.61 -1.39 (-1.36%)
Market Cap
$6.67B
Shares
65.40M
Volume · Nov 18 946.87K Avg daily vol (3M) 1.04M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$102.00 Open$101.44 Day$101.44–102.06 52W close$52.79–110.94 Avg vol 30d1.0M Short int3.6M · 5.6% of shares · 3.2d Short vol30% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 10
Current report 8-K Events of Nov 8
Lantheus agrees to sell CDMO business to PharmaLogic

On November 8, 2026, Lantheus Holdings, Inc. entered into a definitive agreement to sell its CDMO business and Springfield, New Jersey manufacturing facility to PharmaLogic, subject to customary closing conditions. Agilera will also manufacture lutetium Lu 177 dotatate for the company.

Other events
2 source passages
On November 8, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into a definitive agreement with PharmaLogic Holdings Corp. (“PharmaLogic”) to sell its contract development and manufacturing organization (“CDMO”) business and Springfield, New Jersey manufacturing facility to PharmaLogic. In addition, the parties will enter into a long-term supply agreement under which PharmaLogic’s therapeutic CDMO franchise, Agilera, will manufacture lutetium Lu 177 dotatate for the Company. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Lantheus agrees to $102.50 per share cash acquisition

Curium US Holdings LLC will acquire Lantheus for $102.50 per share in cash, plus a contingent value right worth up to $12.00 per share upon commercial milestones; closing is expected in the first half of 2027.

Revenue $389.91M ▲ 1.5% Net income $22.37M ▼ 19.4% Diluted EPS $0.33 ▼ 19.5%
Read from the MD&A section
3 source passages
Agreement and Plan of Merger with Curium US Holdings LLC On August 3, 2026, we entered into the Merger Agreement, pursuant to which, upon the terms and subject to the conditions set forth therein, the Parent will acquire all the outstanding shares of our common stock (other than certain excluded shares and shares for which appraisal rights have been properly exercised) by means of a statutory merger of its subsidiary with and into us (the “Merger”) for $102.50 per share in cash at closing. In addition, as part of the Merger, our stockholders will receive one contingent value right (“CVR”) per share representing the right to receive up to $12.00 per share in cash upon the achievement of certain specified commercial milestones, all subject to the terms and conditions set forth in a CVR agreement to be entered into among the Parent and a rights agent selected by the Parent and reasonably acceptable to us. The transaction is currently expected to close in the first half of 2027, subject to satisfaction of customary closing conditions, including receipt of certain regulatory approvals, including the expiration or termination of the waiting period under the HSR Act, which was extended on October 21, 2026 by the FTC. Lantheus Open the document at this passage
Nov 5
Current report 8-K
Revenue rises amid pending $8.0 billion Curium merger

Lantheus reported third-quarter revenue of $389.9 million, up 1.5%, while adjusted diluted EPS rose to $1.68. Its pending Curium merger is valued at up to approximately $8.0 billion, and full year 2026 guidance was suspended.

Financial results
5 source passages
Lantheus Reports Third Quarter 2026 Financial Results Worldwide revenue increased 1.5% to $389.9 million compared to the same period in 2025. - Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully diluted earnings per share of $0.41 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to $1.27 in the prior year period. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results. Open the document at this passage
Oct 22
Current report 8-K Events of Oct 21
Other events

On October 21, 2026, the Federal Trade Commission issued Second Requests for Lantheus Holdings, Inc.’s merger, extending the HSR Act waiting period until 30 days after substantial compliance unless ended sooner; consummation remains expected in the first half of 2027.

Oct 14
Current report 8-K
Shareholder vote results

On October 14, 2026, Lantheus stockholders approved the August 3, 2026 merger agreement and advisory compensation for named executive officers; the approved adjournment proposal was unnecessary because sufficient votes were cast.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.56B
Trailing 12 months
Net income (TTM)
$269.90M
Trailing 12 months
Revenue growth YoY
+1.5%
Year over year
Operating margin
18.6%
Trailing 12 months
P / E (TTM)
24.9
Trailing earnings · reciprocal yield 4.0%
FCF yield
—
TTM · current market cap
Return on invested capital
18.4%
Trailing 12 months
Net cash
$111.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.1%
Year over year · more shares
Price change (1Y)
+90.7%
Trailing year
Short interest
5.6%
Latest settlement · 3.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very Low
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg +2%
above
RSI (14) 68
neutral
MACD trend Positive
52-week position 85%
mid-range
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +3%
trailing
YTD return +53%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $100 › 200d $94 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +55 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.57% of shares out · ▲ +0.2% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
434 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Fair
Revenue growth +4%
Y/Y
Gross margin 274%
contracting
EPS growth −22%
Y/Y
Valuation P/E 24.9
rich
Buyback $200.0M
remaining
Balance sheet $210.3M
net debt
Quant / Vol
risk profile
Very Low
Volatility 30%
annualized · 1-yr
Max drawdown −12%
past year
ATR 0.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the Earnings Call filed May 7, 2026
Full-year forecasted revenue · full year 2026 $1.4B – $1.45B
prior FY $1.54B midpoint −7.6% Y/Y
Adjusted EPS · full year 2026 Non-GAAP Maintained $5.00 – $5.25
Feb 26, 2026 $5.00 – $5.25 changed to May 7, 2026 $5.00 – $5.25
Guided vs delivered · last 8 settled
FY 2025 Revenue FY 2025
guided $1.49B – $1.51B
$1.54B Beat +2.8%
FY 2024 Revenue FY 2024
guided $1.5B – $1.52B
$1.53B Beat +1.6%
Q2 FY 2024 Revenue Q2 FY 2024
guided $380M – $390M
$394.09M Beat +2.4%
Revenue 1Q 2024
guided $347M – $355M
$369.98M Beat +5.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
68 Neutral
MACD trend
Positive Bullish
52-week position
85% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $100 › 200d $94 — 50d above 200d
Institutional flow Distributing
-8% holders QoQ · +55 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.57% of shares out · ▲ +0.2% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
434 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $53 Now $102 · 85% Range high $111
vs 200-day avg +9% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted net income non-GAAP 200.75M Six Months Ended June 30 —
Adjusted net income per share - diluted non-GAAP $3.02 Six Months Ended June 30 —
Adjusted net income, as a percentage of revenues non-GAAP 26.2% Six Months Ended June 30 —
Adjusted operating income non-GAAP 271.16M Six Months Ended June 30 —
Adjusted operating income, as a percentage of revenues non-GAAP 35.4% Six Months Ended June 30 —
Free cash flow non-GAAP 211.77M Six Months Ended June 30 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LNTH
Lantheus Holdings, Inc.
this stock
$6.67B +53.3% +3.6% 24.9 5.6%
TAK
Takeda Pharmaceutical Co Ltd
$67.96B +36.4% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.28B +35.3% +4.3% 96.0 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
434
% held
99.2%
Net QoQ
-10.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
477
View
Short & Settlement
Short Interest Rising
Shares short
3.6M
Days to cover
3.2d
Change
+8.5K sh
View
Short Volume
Short vol %
30%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
326
Value
$32.5K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
63.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Oct 15, 2026
View
Financials
Financials
Revenue (FY)
$1.5B
Net income (FY)
$233.6M
EPS diluted
$3.41
View
Buybacks
Authorized
$400.0M
Remaining
$200.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 10, 2026
This year
32

On November 8, 2026, Lantheus Holdings, Inc. entered into a definitive agreement to sell its CDMO business and Springfield, New Jersey manufacturing facility to PharmaLogic, subject to customary closing conditions. Agilera will also manufacture lutetium Lu 177 dotatate for the company.

View
Proposed Sales
Value
$449.6K
Shares
6.7K
Filed
Feb 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Lantheus Welcomes CMS CY27 Final…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
LNTH +0.4% +1.8% +2.7% +1.5% +53.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +4.3% +7.3% +6.2% +4.9% +46.2%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$400.00M
Spent (derived)
$200.00M
Remaining
$200.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1521036 CUSIP 516544103 13F (30d) 450 filings 402 filers Visit website Investor relations